Li Watsek
Stock Analyst at Cantor Fitzgerald
(3.29)
# 2,071
Out of 5,161 analysts
80
Total ratings
55.42%
Success rate
0.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZLAB Zai Lab | Maintains: Overweight | $55 → $37 | $18.87 | +96.08% | 2 | Feb 27, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | n/a | $36.00 | - | 1 | Feb 24, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Overweight | n/a | $24.10 | - | 1 | Dec 23, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | n/a | $5.19 | - | 1 | Dec 3, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $203 → $254 | $229.01 | +10.91% | 20 | Oct 13, 2025 | |
| CNTX Context Therapeutics | Initiates: Overweight | n/a | $3.09 | - | 1 | Oct 2, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $32.83 | - | 3 | Sep 9, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $7.58 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $8.84 | - | 11 | Jun 26, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.61 | - | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $5.32 | - | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.48 | - | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.02 | - | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.70 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.04 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.01 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.01 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $5.03 | -40.36% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.17 | +327.35% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.29 | +1,559.39% | 1 | Aug 12, 2022 |
Zai Lab
Feb 27, 2026
Maintains: Overweight
Price Target: $55 → $37
Current: $18.87
Upside: +96.08%
Tyra Biosciences
Feb 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $36.00
Upside: -
ArriVent BioPharma
Dec 23, 2025
Initiates: Overweight
Price Target: n/a
Current: $24.10
Upside: -
Compass Therapeutics
Dec 3, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.19
Upside: -
Ascendis Pharma
Oct 13, 2025
Maintains: Overweight
Price Target: $203 → $254
Current: $229.01
Upside: +10.91%
Context Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.09
Upside: -
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $32.83
Upside: -
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $7.58
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.84
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.61
Upside: -
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.32
Upside: -
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $12.48
Upside: -
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.02
Upside: -
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.70
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.04
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.01
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.01
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $5.03
Upside: -40.36%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.17
Upside: +327.35%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.29
Upside: +1,559.39%